Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

322 results
Display

How to predict treatment failure in frail patients with advanced epithelial ovarian cancer: strategies to personalize surgical effort

Fotopoulou C

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer

Park J, Eoh KJ, Nam EJ, Kim S, Kim SW, Kim YT, Lee JY

PURPOSE: We evaluated whether adding bevacizumab to current platinum-based chemotherapy could improve clinical outcomes without affecting safety. MATERIALS AND METHODS: We retrospectively reviewed medical records of patients with pathologically confirmed ovarian...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Germline PALB2, ATM variants in a patient with breast and ovarian cancer at risk for familial cancer syndrome: Is there a role for risk-reducing salpingo-oophorectomy?

Carbajal-Mamani SL, Markham MJ, Santolaya-Forgas J, Castagno J, Cardenas-Goicoechea J

A 50-year-old non-Hispanic white Caucasian female was diagnosed with breast cancer and was subsequently found to possess the tumorigenic ataxia telangiectasia mutated (ATM) and PALB2 variants but not the BRCA1...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Robotic-assisted interval cytoreductive surgery in ovarian cancer: a feasibility study

Carbajal-Mamani SL, Schweer D, Markham MJ, Esnakula A, Grajo JR, Castagno J, Cardenas-Goicoechea J

OBJECTIVE: The primary objective was to assess the feasibility of robotic-assisted interval cytoreductive surgery for achieving complete cytoreduction for patients with advanced-stage ovarian cancer. The secondary objective was to examine...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer

Kim YN, Lee YJ, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT

OBJECTIVE: To compare the efficacy and toxicity of dose-dense weekly paclitaxel and 3-weekly carboplatin (ddPC) as neoadjuvant chemotherapy (NAC) with the standard 3-weekly regimen. METHODS: A retrospective study of patients diagnosed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tozzi classification of diaphragmatic surgery in patients with stage IIIC–IV ovarian cancer based on surgical findings and complexity

Tozzi R, Ferrari F, Nieuwstad , Campanile , Soleymani Majd H

OBJECTIVE: To introduce a systematic classification of diaphragmatic surgery in patients with ovarian cancer based on disease spread and surgical complexity. METHODS: For all consecutive patients who underwent diaphragmatic surgery during...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis

Lv X, Cui S, Zhang X, Ren C

OBJECTIVE: Neoadjuvant chemotherapy (NACT) for the treatment of epithelial ovarian cancer (EOC) has remained controversial. This meta-analysis was performed to systematically assess the efficacy and safety of NACT versus primary...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery

Liu YL, Filippova OT, Zhou Q, Iasonos A, Chi DS, Zivanovic O, Sonoda Y, Gardner GJ, Broach VA, O'Cearbhaill RE, Konner JA, Aghajanian C, Long Roche K, Tew WP

OBJECTIVE: Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) confers similar outcomes as primary debulking surgery and chemotherapy. Little is known about patients who receive NACT but do not...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Factors associated with surgical morbidity of primary debulking in epithelial ovarian cancer

Günakan E, Tohma YA, Tunç M, Akıllı H, Şahin H, Ayhan A

OBJECTIVE: Epithelial ovarian cancer (EOC) requires an aggressive surgical approach. The important part of literature on ovarian cancer surgery emphasize residual tumor and survival analyses. Morbidity issue keeps in background....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Response to comment on: prior uterine myoma and risk of ovarian cancer: a population-based case-control study

Huang CC, Lin CH

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Letter to editor in response to: prior uterine myoma and risk of ovarian cancer: a population-based case-control study

Oxley SG, Sirkeci F, Odejinmi F

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
How to use immune checkpoint inhibitor in ovarian cancer?

Park J, Lee JY, Kim S

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Aromatase inhibition in ovarian cancer: repeated signals of efficacy but tools for patient selection remain elusive

Gourley C

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression

Kok PS, Beale P, O'Connell , Grant P, Bonaventura T, Scurry J, Antill Y, Goh J, Sjoquist K, DeFazio A, Mapagu C, Amant F, Friedlander M, on behalf of the PARAGON Investigators

OBJECTIVE: A subset of patients with recurrent ovarian cancer (ROC) may benefit from antiestrogen therapy with higher response rates reported in tumors that are strongly estrogen receptor (ER)-positive (ER+). PARAGON...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?

Yoneoka Y, Ishikawa M, Uehara T, Shimizu H, Uno M, Murakami T, Kato T

OBJECTIVE: To treat advanced ovarian cancer, interval debulking surgery (IDS) is performed after 3 cycles each of neoadjuvant chemotherapy (NAC) and postoperative chemotherapy (IDS group). If we expect that complete...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Overexpression of HER2/HER3 and clinical feature of ovarian cancer

Chung YW, Kim S, Hong JH, Lee JK, Lee NW, Lee YS, Song JY

OBJECTIVES: Human epidermal growth factor receptor-2 (HER2) and 3 (HER3) belong to the epidermal growth factor receptor (EGFR) family of transmembrane receptor tyrosine kinases. In this study, we assessed HER2/HER3...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prior uterine myoma and risk of ovarian cancer: a population-based case-control study

Tseng JJ, Huang CC, Chiang HY, Chen YH, Lin CH

OBJECTIVE: Uterine myoma which results in the magnitude of ovarian cancer remains uncertain. This study aimed to assess the association between women with previous uterine myoma and the risk of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Involved-field radiation therapy for selected cases of recurrent ovarian cancer

Kim N, Chang JS, Kim SW, Kim GM, Lee JY, Kim YB

OBJECTIVES: In our institutional experience, involved-field radiation therapy (IFRT) yields favorable outcomes in patients with recurrent epithelial ovarian cancer (EOC). This retrospective study aimed to investigate the clinical benefits of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer

Kim SI, Song M, Hwangbo S, Lee S, Cho U, Kim JH, Lee M, Kim HS, Chung HH, Suh DS, Park T, Song YS

PURPOSE: Discovery of models predicting the exact prognosis of epithelial ovarian cancer (EOC) is necessary as the first step of implementation of individualized treatment. This study aimed to develop nomograms...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Genetic Profiles Associated with Chemoresistance in Patient-Derived Xenograft Models of Ovarian Cancer

Li LY, Kim HJ, Park SA, Lee SH, Kim LK, Lee JY, Kim S, Kim YT, Kim SW, Nam EJ

PURPOSE: Recurrence and chemoresistance (CR) are the leading causes of death in patients with high-grade serous carcinoma (HGSC) of the ovary. The aim of this study was to identify genetic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr